Metrics to compare | 6704 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6704PeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.3x | −31.9x | −0.2x | |
PEG Ratio | 0.45 | −0.67 | 0.00 | |
Price/Book | 2.6x | 3.2x | 2.6x | |
Price / LTM Sales | 12.1x | 61.2x | 2.8x | |
Upside (Analyst Target) | - | 68.6% | 60.9% | |
Fair Value Upside | Unlock | 0.2% | 9.5% | Unlock |
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.